Company / R&D per Share
Regeneron Pharmaceuticals R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$51.45
FY2025
5-year range
$21.38 / $51.45
FY2021-FY2025
Trend
+13.8%
vs FY2024
Sector context
#4 of 208
Health Care
What the data says
Among 208 Health Care companies, Regeneron Pharmaceuticals is in the top 2% for r&d per share. R&D per Share has increased for 5 consecutive years, from $12.79 in FY2020 to $51.45 in FY2025.
Based on SEC 10-K filings.
51.45 in FY2025 with a 5-year CAGR of +32.1%. Top quartile in the Health Care sector.
Improved from $39.56 to $51.45 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +30.8%
- 5-Year CAGR
- +32.1%
- 10-Year CAGR
- -
Sector benchmark
Top 2% in Health CareTop 2% of 208This company $51.45 Sector average $28.82
▼
+78.5% above sector average
Key checks
Key Insights
- Regeneron Pharmaceuticals's r&d per share has grown for 5 consecutive years.
- In FY2025, r&d per share increased 13.8% year-over-year.
- Ranks #4 out of 208 companies in the Health Care sector.
- Lowest r&d per share in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 3.03 (safe zone, above 2.9 threshold)
- Strong profit margin: 32.1%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $51.45 | +13.8% |
| FY2024 | $45.22 | +14.3% |
| FY2023 | $39.56 | +72.0% |
| FY2022 | $23.00 | +7.6% |
| FY2021 | $21.38 | +67.1% |
| FY2020 | $12.79 | -39.5% |
| FY2019 | $21.14 | +67.4% |
| FY2018 | $12.63 | -29.9% |
| FY2017 | $18.01 | -0.5% |
| FY2016 | $18.10 | +24.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026